AUSTIN,
Texas, April 6, 2022 /PRNewswire/ -- VolitionRx
Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national
epigenetics company, has announced the appointment of Sharon Ballesteros as U.S Head of Quality and
Development Process.
Sharon has over 20 years of experience within the in vitro
diagnostics industry with senior program management, quality
assurance, and process improvement roles at Siemens Health
Diagnostics, Thermo Fisher, and
Agena Bioscience. Most recently, Sharon was Director of Design
Quality and Risk at GRAIL where she led the company's Design
Controls and Risk programs.
Sharon joins Volition America, Volition's wholly owned U.S.
subsidiary, as the company expands its team and operations in
California, and opens a new 6,000
ft state-of-the-art innovation laboratory in Carlsbad focused on cutting-edge, discovery
research.
Gaetan Michel, Chief Operating
Officer of Volition, said, "We're delighted to welcome Sharon to
Volition. Her leadership skills, industry knowledge and expertise
in quality assurance, regulatory affairs and process improvement
will be invaluable to us, as we develop and implement a robust
clinical study and FDA regulatory program, and help bring our range
of Nu.Q® products to market."
Commenting on her appointment, Sharon
Ballesteros said, "I am excited to join Volition at such a
pivotal stage, as the company transitions from an R&D company
to a commercial operation and focuses on its product realization
and regulatory strategies. Volition is dedicated to revolutionizing
the diagnosis and monitoring of life-altering diseases, through its
transformative Nucleosomics™ technology, and I look forward to
working with Volition's expert team."
Volition is developing simple, easy-to-use, cost-effective blood
tests to help diagnose and monitor a range of life-altering
diseases including cancer in both humans and animals. For more
information about Volition's Nu.Q® technology go to:
www.volition.com
About Volition
Volition is a multi-national epigenetics company that applies
its Nucleosomics™ platform through its subsidiaries to develop
simple, easy to use, cost effective blood tests to help diagnose
and monitor a range of life-altering diseases including some
cancers and diseases associated with NETosis such as sepsis and
COVID-19. Early diagnosis and monitoring have the potential to not
only prolong the life of patients but also improve their quality of
life. The tests are based on the science of Nucleosomics™, which is
the practice of identifying and measuring nucleosomes in the
bloodstream or other bodily fluid - an indication that disease is
present. Volition is primarily focused on human diagnostics and
monitoring but also has a subsidiary focused on animal diagnostics
and monitoring.
Volition's research and development activities are centered in
Belgium, with an innovation
laboratory in California and
additional offices in Texas,
London, and Singapore, as the company focuses on bringing
its diagnostic and disease monitoring products to market.
For more information about Volition, visit Volition's website or
connect with us via Twitter, LinkedIn, and Facebook.
Media Enquiries:
Louise Batchelor/Debra Daglish, Volition,
mediarelations@volition.com +44 (0)7557 774620
Investor Enquiries:
Scott Powell, Volition,
investorrelations@volition.com +1 (646) 650 1351
Joseph Green, Edison Advisors,
jgreen@edisongroup.com +1 (646) 653 7030
Safe Harbor Statement
Statements in this press release may be "forward-looking
statements" within the meaning of Section 27A of the Securities Act
of 1933, as amended, and Section 21E of the Securities Exchange Act
of 1934, as amended, that concern matters that involve risks and
uncertainties that could cause actual results to differ materially
from those anticipated or projected in the forward-looking
statements. Words such as "expects," "anticipates," "intends,"
"plans," "aims," "targets," "believes," "seeks," "estimates,"
"optimizing," "potential," "goal," "suggests," "can," "could,"
"would," "should," "may," "will" and similar expressions identify
forward-looking statements. These forward-looking statements relate
to the effectiveness of Volition's blood-based diagnostic,
prognostic and disease monitoring tests, Volition's ability to
develop and successfully commercialize such test platforms for
early detection of cancer and other diseases as well as serving as
a diagnostic, prognostic or disease monitoring tools for such
diseases, and the timing of product launches and publications.
Volition's actual results may differ materially from those
indicated in these forward-looking statements due to numerous risks
and uncertainties, including, without limitation, results of
studies testing the efficacy of its tests. For instance, if
Volition fails to develop and commercialize diagnostic, prognostic
or disease monitoring products, it may be unable to execute its
plan of operations. Other risks and uncertainties include
Volition's failure to obtain necessary regulatory clearances or
approvals to distribute and market future products; a failure by
the marketplace to accept the products in Volition's development
pipeline or any other diagnostic, prognostic or disease monitoring
products Volition might develop; Volition's failure to secure
adequate intellectual property protection; Volition will face
fierce competition and Volition's intended products may become
obsolete due to the highly competitive nature of the diagnostics
and disease monitoring markets and their rapid technological
change; downturns in domestic and foreign economies; and other
risks identified in Volition's most recent Annual Report on Form
10-K and Quarterly Reports on Form 10-Q, as well as other documents
that Volition files with the Securities and Exchange Commission.
These statements are based on current expectations, estimates and
projections about Volition's business based, in part, on
assumptions made by management. These statements are not guarantees
of future performance and involve risks, uncertainties and
assumptions that are difficult to predict. Forward-looking
statements are made as of the date of this release, and, except as
required by law, Volition does not undertake an obligation to
update its forward-looking statements to reflect future events or
circumstances.
Pursuant to the disclosure requirements of the NYSE American
Company Guide Section 711(a), Volition is reporting that its Board
of Directors (including all of its independent directors) has
approved the issuance of a warrant to purchase up to 54,000 shares
of Volition common stock (the "Warrant") to Sharon Ballesteros as a material inducement for
her entering employment with Volition America, Inc., Volition's
wholly owned subsidiary, as U.S. Head of Quality and Development
Process. The Warrant was granted effective April 4, 2022, with an exercise price of
$3.05 per share and vests in two
equal installments of 27,000 shares on each of April 4, 2023, and April
4, 2024, respectively, (subject to (i) continued employment
through such date, and (ii) the shares underlying the Warrant shall
have been duly approved for listing by the NYSE American prior to
exercise). Each installment of the Warrant will expire five years
after vesting on each of April 4,
2028, and April 4, 2029,
respectively.
Nucleosomics™ and Nu.Q® and their respective logos
are trademarks and/or service marks of VolitionRx Limited and its
subsidiaries. All other trademarks, service marks and trade names
referred to in this press release are the property of their
respective owners.
View original
content:https://www.prnewswire.com/news-releases/volition-appoints-sharon-ballesteros-as-us-head-of-quality-and-development-process-301518777.html
SOURCE VolitionRx Ltd